2025/12/29
• Posted by Provider Relations
Fidelis Care will host three Provider Office Hours in January 2026. During the webinar, Fidelis Care staff will be available to share information, provide an overview of provider resources, and answer your questions.
Provider Office Hours – January 2026
Topic: Fidelis Care – Back to Basics
When: Thursday, January 8th – 9AM – 10AM EST
Click here to register*
Topic: Fidelis Care and Wellcare Quality Programs
When: Wednesday, January 21st – 10AM – 11AM EST
Click here to register*
2025/12/29
• Posted by Provider Relations
The following sections of the Fidelis Care authorization grids have been updated effective February 1, 2026.
The following codes have been added to the Medicaid DME Authorization Grid and require prior authorization:
E0766 Electrical stimulation device used for cancer treatment, includes all accessories, any type
E2606 Positioning wheelchair seat cushion, width 22 inches or wider
Visit: Authorization Grids
2025/12/29
• Posted by Provider Relations
Fidelis Care is pleased to announce that a new Provider Bulletin is now available. The bulletin features updates on important initiatives and the latest news of interest to our provider community.
Articles in this issue:
· Help Prevent the Flu: Encourage Vaccination
· COVID-19 Reminder
· Cardiovascular Disease and Statin Therapy
· Antibiotic Stewardship Starts with Awareness
· CDC Recommendations for STI Treatment
Please download Fidelis Care Provider Bulletin – Volume 11, Issue 4.
To view our Provider Bulletin Library, please visit: Provider Bulletins.
2025/12/10
• Posted by Provider Relations
The following sections of the Fidelis Care authorization grids have been updated effective January 1, 2026.
The following codes have been updated on the Medicaid, CHP, Essential Plan, AmBetter Metal-Level Plans, and Medicare Authorization Grids and require prior authorization:
C9307 linvoseltamab-gcpt inj
C9308 carboplatin (Avyxa) inj
J0013 esketamine, nasal spray
J1073 testosterone pellet, implant
J3387 elivaldogene autotemcel (Skysona)
J3389 prademagene zamikeracel (Zevaskyn)
J7528 mycophenolate mofetil, suspension
J9184 gemcitabine (Avyxa) inj
J9256 nipocalimab-aahu inj
J9282 mitomycin intravesical
J9326 telisotuzumab vedotin-tllv inj (Emrelis)
Q5160 bevacizumab-nwgd (Jobevne)
For Medicaid, CHP, Essential Plan, AmBetter Metal-Level Plans, and Medicare, the following codes have been added to the list of drugs that require NCH review:
C9307 linvoseltamab-gcpt inj
C9308 carboplatin (Avyxa) inj
J9184
Newer Articles
Older Articles